The FDA has approved Simtriyo, a nonstimulant daily pill for ADHD in children, teens, and adults. Here’s more on potential ...

For decades, ADHD was viewed as a childhood condition that mostly affected boys. Researchers now know ADHD manifests ...

University of Iowa Health Care has completed a major renovation and expansion of Iowa's only burn treatment center, ...

Doctors are now using tumor‑infiltrating lymphocyte (TIL) therapy, a newly FDA‑approved treatment for advanced melanoma, to supercharge a patient’s own immune system.

New research reveals ADHD isn't one-size-fits-all — covering social media's specific role, why medication rarely 'stops ...

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

An 18-year sibling-design study in Psychiatry Research finds that childhood ADHD more than doubles adult depression risk and ...

The FDA approved Simtriyo (centanafadine), making it the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit hyperactivity ...

If social media is to be believed, ADHD can be managed with supplements, breathing exercises, herbal remedies, and just about ...

The FDA has approved Simtriyo (centanafadine) as the first norepinephrine, dopamine, serotonin reuptake inhibitor for adult and pediatric ADHD.

Groundbreaking research found that behavioral therapy – when used first – was less expensive and more effective than medication in treating children with ADHD.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of ...